MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology
March 28, 2023
![MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology](/media/uploads/en/news/thumb/logo_Mimetas_8.jpg?_=1680013184)
Leiden, the Netherlands , March 28, 2023 / B3C newswire / -- MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company. The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.
“We are excited to make this next step in our longstanding collaboration with Astellas,” Paul Vulto, CEO of MIMETAS, says. “Astellas is among Japan's most innovative pharmaceutical companies with ambitious programs on cancer cell therapies and bispecific immune cell engagers. MIMETAS has the expertise and technology to capture the complexity of tumors and their microenvironments. This crucial piece of a puzzle allows us to understand tumor biology more deeply and supports Astellas’ ambition to substantially increase response rate to immuno-oncological treatments.”
Under the partnership, Astellas will receive access to MIMETAS immune oncological disease assays. MIMETAS will be eligible for upfront and milestone payments.
About MIMETAS
MIMETAS (Leiden, The Netherlands) is a global leader in disease modeling using organ-on-a-chip technologies. Its proprietary OrganoPlate® platform enables the development and high-throughput screening of physiologically relevant disease models for drug discovery and development. The company offers its technology and expertise in therapy co-development projects, services, and off-the-shelf products. MIMETAS works with leading pharmaceutical and biotech companies worldwide to develop novel therapies against unsolved diseases. Founded in 2013 in Leiden, the Netherlands, MIMETAS has grown into a multinational company with operations in Europe, Asia, and the USA. To learn more about MIMETAS' disease modeling capabilities and its OrganoPlate® platform, visit www.mimetas.com